Sumatriptan and Pulmonary embolism - a phase IV clinical study of FDA data

Summary:

Pulmonary embolism is reported as a side effect among people who take Sumatriptan (sumatriptan succinate), especially for people who are female, 40-49 old, have been taking the drug for < 1 month also take Yaz, and have Birth control.

The phase IV clinical study analyzes which people have Pulmonary embolism when taking Sumatriptan. It is created by eHealthMe based on reports of 17,179 people who have side effects when taking Sumatriptan from the FDA, and is updated regularly.

What is Sumatriptan?

Sumatriptan has active ingredients of sumatriptan succinate. It is often used in migraine. eHealthMe is studying from 18,159 Sumatriptan users. Check the latest studies of Sumatriptan.

What is Pulmonary embolism?

Pulmonary embolism (blockage of the main artery of the lung) is found to be associated with 2,333 drugs and 2,956 conditions by eHealthMe. Check the latest studies of Pulmonary embolism.

On Jul, 06, 2026

17,179 people reported to have side effects when taking Sumatriptan.
Among them, 126 people (0.73%) have Pulmonary embolism.

Could Sumatriptan cause Pulmonary embolism?

Among these 126 people:

How long have people been on Sumatriptan when they have Pulmonary embolism? *

Click here to view more results

What is the gender of people who have Pulmonary embolism when taking Sumatriptan? *

Click here to view

What is the age of people who have Pulmonary embolism when taking Sumatriptan? *

Click here to view more results

* Approximation only. Some reports may have incomplete information.

Do you take Sumatriptan and have Pulmonary embolism?

- Check whether Pulmonary embolism is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Sumatriptan:

Sumatriptan (18,159 reports)

Pulmonary embolism treatments and more:

Pulmonary embolism (160,407 reports)

How severe was Pulmonary embolism and when was it recovered:

Pulmonary embolism in Sumatriptan

Expand to all the drugs that have ingredients of sumatriptan succinate:

Pulmonary embolism and drugs with ingredients of sumatriptan succinate (469 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Sumatriptan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Pulmonary embolism:

Pulmonary embolism (2,333 drugs)

Browse all the conditions that are associated with Pulmonary embolism:

Pulmonary embolism (2,956 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on sumatriptan succinate (the active ingredients of Sumatriptan) and Sumatriptan (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.